Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
Glaucoma: Overview01:25

Glaucoma: Overview

1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

252
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
252
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

1.1K
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
1.1K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

580
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
580

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of and risk factors for diabetic retinopathy: The Thessaloniki Eye Study.

Eye (London, England)·2026
Same author

The Future of Glaucoma: Data, AI, and Precision Medicine for Patient-Centered Care.

Journal of glaucoma·2026
Same author

Real-world integration of an autonomous artificial intelligence system for diabetic retinopathy screening in an endocrinology outpatient clinic.

The British journal of ophthalmology·2026
Same author

Stresses and fluid flow in lamina cribrosa through anisotropic poroelasticty.

ArXiv·2026
Same author

Stresses and fluid flow in lamina cribrosa through anisotropic poroelasticity.

Biomechanics and modeling in mechanobiology·2026
Same author

A theoretical model for the influence of age, race and ethnicity on retinal mitochondria dysfunction.

Journal of theoretical biology·2026
Same journal

CORRIGENDUM TO: Recent advances in the diagnosis and management of pre-eclampsia.

F1000prime reports·2015
Same journal

Ethylene receptors in plants - why so much complexity?

F1000prime reports·2015
Same journal

Hematopoietic transcription factor mutations and inherited platelet dysfunction.

F1000prime reports·2015
Same journal

Advancing our knowledge of the complexity and management of intimate partner violence and co-occurring mental health and substance abuse problems in women.

F1000prime reports·2015
Same journal

Recent advances in understanding and managing cystic fibrosis transmembrane conductance regulator dysfunction.

F1000prime reports·2015
Same journal

Insomnia and sleep apnea in midlife women: prevalence and consequences to health and functioning.

F1000prime reports·2015
See all related articles

Related Experiment Video

Updated: Apr 18, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.8K

Novel therapies for open-angle glaucoma.

Scott M Wentz1, Nathaniel J Kim1, Jenny Wang1

  • 1Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine 1160 W Michigan St, Indianapolis, IN 46202 USA.

F1000Prime Reports
|January 13, 2015
PubMed
Summary
This summary is machine-generated.

Open-angle glaucoma, an irreversible optic neuropathy, currently lacks a cure. Future treatments require novel approaches beyond lowering intraocular pressure, focusing on neuroprotection and improved drug delivery for better patient outcomes.

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

2.1K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

2.0K

Related Experiment Videos

Last Updated: Apr 18, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.8K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

2.1K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

2.0K

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Pharmacology

Background:

  • Open-angle glaucoma is a progressive optic neuropathy causing irreversible retinal ganglion cell loss.
  • Current treatments focus solely on lowering intraocular pressure, a known risk factor.
  • Glaucoma pathophysiology involves multiple factors beyond intraocular pressure.

Purpose of the Study:

  • To explore novel therapeutic targets and strategies for managing open-angle glaucoma.
  • To identify new approaches for neuroprotection of retinal ganglion cells.
  • To investigate advanced drug delivery systems for glaucoma treatment.

Main Methods:

  • Review of current literature on glaucoma pathophysiology and treatment.
  • Analysis of emerging therapeutic targets including ocular hemodynamics and neuroprotection.
  • Evaluation of novel drug delivery systems for enhanced bioavailability and compliance.

Main Results:

  • Identification of multiple risk factors contributing to glaucoma's progression.
  • Potential for new therapies targeting ocular hemodynamics and neuroprotection.
  • Development of innovative drug delivery systems to improve treatment efficacy.

Conclusions:

  • Current glaucoma treatments are insufficient due to the multifactorial nature of the disease.
  • Future advancements necessitate a broader therapeutic approach, including neuroprotection and improved drug delivery.
  • Novel strategies are crucial for enhancing patient compliance and treatment outcomes in open-angle glaucoma management.